TAK-438 Of Takeda Enters Phase II Clinical Trials
Takeda Pharmaceutical (Takeda) has reported that TAK-438, an acid-related diseases drug, has entered into Phase II clinical trials for the treatment of patients with reflux esophagitis in Japan.
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
Aterovax has announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD)
“At Loyola, we determined four years ago that the rapid tests for influenza detected only 50 percent of the patients who were positive,” said Paul Schreckenberger, Ph.D., director